FastCompany RSS

Topic: Vioxx

  
   |  Comment

A discussion on HealthGrid technology and Private Equity with Dr. Jonathan Silverstein

 As we continue to search for value in the highly volatile market, it's clear that the value will lie in areas that don't have electronic price quotations which can be delivered at lightspeed by fingers adept with command ...READ»

   |  Comment

The CSR Industry's Lost Cause

What does the 2009 CRO 100 Best Corporate Citizens list say about the current state of the CSR industry? Perhaps it’s time for a makeover. READ»

   |  Comment

Did Merck Really Try to Deliberately Silence Critics?

Disturbing article on Total Health Breakthroughs about a deliberate campaign by Merck to intimidate, defund ,and otherwise make life miserable for doctors who dared to speak out about the nasty and sometimes-lethal side effects of ...READ»

   |  Comment

Manufacturing Doubt in Product Defense

What is the product-defense industry? How does it work, and who's behind it? We asked David Michaels, author of the exposé Doubt Is Their Product.READ»

   |  Comment

Spit Party

The Fast Interview: The co-founders of 23andMe talk about mixing social media and genetics, a predisposition for Brussel sprouts, and being married to Google's Sergey Brin.READ»

   |  Comment

Business Left Undone

Bill McGuire left UnitedHealth in the wake of an options scandal. While he awaits his fate, he refocuses on his great passion: reforming health care.READ»

   |  Comment

JetBlue and Merck: Whom do you trust?

JetBlue is having its own Katrina crisis, but they will emerge successfully not just because they have a CEO willing to listen and learn, but because they have so much goodwill in the image bank that there's enough reserve currency ...READ»

   |  Comment

Pain-Free Day for Big Pharma

An FDA advisory panel today recommended that recently controversial drugs Celebrex, Vioxx, and Bextra remain on the market, albeit with some restrictions. The panel acknowledged that the drugs can cause heart attacks and strokes, but ...READ»